Quick Answer
Regencell Bioscience Holdings Ltd reported R&D Expense of $948.3 thousand for fiscal year 2025.
Regencell Bioscience Holdings Ltd R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $948.3K | -11.1% |
| 2024 | $1.07M | -32.6% |
| 2023 | $1.58M | -37.0% |
| 2022 | $2.51M | +473.1% |
| 2021 | $438.3K | +13.5% |
| 2020 | $386.2K | +69.2% |
| 2019 | $228.2K | — |
- Regencell Bioscience Holdings Ltd showed a decrease of -11.1% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Regencell Bioscience Holdings Ltd’s r&d expense has grown by 315.5% (from $228.2 thousand to $948.3 thousand).
- The most recent figure is from Regencell Bioscience Holdings Ltd’s fiscal year 2025 report (Form 20-F), filed with the SEC on October 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: